about
TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.Association of Oesophageal Varices and Splanchnic Vein Thromboses in Patients with JAK2-Positive Myeloproliferative Neoplasms: Presentation of Two Cases and Data from a Retrospective Analysis.Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).Stem cell transplantation for patients with Evans syndrome.Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors.Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis.Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cellsOutcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST).MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells¹⁸F-FDG-PET/CT for detection of extramedullary acute myeloid leukemiaTherapy-related myeloid neoplasms following treatment with radioiodine.A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyTreatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO.Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidineQuantitative analyses of DAPK1 methylation in AML and MDSFive-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndromeParameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.Optimizing management of myelodysplastic syndromes post-allogeneic transplantation.Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop.
P50
Q27853319-3874AC05-DD66-406E-882A-BB2CAF989269Q28066544-AD38FA94-0DE0-4165-A62A-9389368FB965Q30313209-41D4B53C-B805-4738-8938-3FCB8284854DQ30316874-FA51C89C-7451-44BF-B068-BB6D043C4786Q30658101-C0589770-FB12-40BD-A849-B00951A9132DQ33383048-EB036B29-4A4A-4AD0-8044-50495634367BQ33389601-44954178-08AA-48B6-BF06-DD41B7A2EB2FQ33409020-D02326A4-9BA3-4D6B-88DF-FAC19830DB92Q33414453-DD875694-5EA3-4090-87D6-4CDA0396E1AEQ33416541-E11810F7-95E2-4FF1-8003-629CCA0C737BQ33428549-5C2F3B79-5F04-464A-BA9F-8434E3C28B77Q33430655-904467E6-B2FC-4044-9BF9-FABFFDE2026AQ33433485-6EDF8562-17D7-4508-B822-F597DBFCB6C3Q33822010-3B35E0AC-5A22-4321-963C-26CF23F3FC52Q33905984-1FFF8D92-768E-4660-AD3A-494F19E67212Q34502726-A61AE300-3ED5-472D-963C-C49828D483FDQ34516294-AD1648E3-E959-4B76-89F2-2D506FBE54F2Q34523534-022FDA51-7AF2-4F54-BAB2-B2C4B9B311B0Q34649548-6642FC43-613E-4DD1-AF47-DBA736D095E6Q35105333-F298EA48-F434-49CA-9168-0D97CF1DDCECQ35266033-2BB9409F-6ABC-44EE-B409-446F2B8549F2Q35717790-C44AC2DE-59B2-4F82-A458-B6A52A9DE1B9Q35794439-B19A2E61-EDB0-4910-A2DB-106EADBD830EQ35904262-BD909F8B-ACCE-49B3-951B-17658540E916Q35962533-6E915D9C-5CB9-4B8B-AE49-BC47BAAB3D60Q36029093-F3143112-BCCB-4D15-877F-CFCEF0ED010FQ36296317-92AA8EFB-35B9-4BCE-8EAB-1199B8400DCEQ36339459-9400B4BC-7354-48AC-B787-704656A42FFAQ36509631-2EC0F46A-C80B-4D13-BAF1-56C84B2CB7E7Q36544315-8FF0F6A5-F269-4637-9528-F7904B71E0BDQ36579081-1108F114-D204-4A1D-B81C-5470F4B3A78CQ36715932-1564D3EE-BE0D-42A4-8AC4-4BC55F141D45Q36909178-6D7016CF-297F-4D59-BDC7-D2C799269B88Q36993026-F1BAAFC8-E385-45A3-A37C-3A9B3C87D01EQ37263146-CCE4A4EF-7733-4810-8119-08B65516A107Q37273157-1B66046B-B6C9-445D-8063-1EC040CB5609Q37380958-C8B825DE-8C48-4DC1-A071-520D42098AD1Q37766785-D1212632-8FD5-44B3-B04B-44D0C1F89209Q37955235-56F575AA-EA9D-47E4-A655-BF2E0F2528A8Q37964178-B191EBB7-5401-4D24-9304-9BAA67CBBA34
P50
name
Uwe Platzbecker
@en
Uwe Platzbecker
@nl
type
label
Uwe Platzbecker
@en
Uwe Platzbecker
@nl
prefLabel
Uwe Platzbecker
@en
Uwe Platzbecker
@nl